Prior work has linked participant-rated cognitive decline to cerebrospinal fluid (CSF) biomarkers, showing subtle relationships between increased participant-reported cognitive concerns and higher CSF tau levels or lower CSF Aβ levels (Wolfsgruber et al., 2015; Miebach et al., 2019; Espenes et al., 2020). The gene discussed is MAPT; the disease is Mental deterioration.